Kirk R. Schultz
Expertise in
8
conditions

Kirk R. Schultz

Vancouver, BC, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Vancouver, BC, CA 
OverviewLocationsClinical Research

Overview

Kirk Schultz practices in Vancouver, Canada. Mr. Schultz is highly rated in 8 conditions, according to our data. His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Tissue Biopsy.

His clinical research consists of co-authoring 187 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Vancouver, BC, Canada
Other Locations
BC, Canada
Burnaby, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: ITMHA, Dexamethasone, Mitoxantrone, Pegaspargase, Asparaginase Erwinia Chrysanthemi, Bortezomib, Vorinostat, Cyclophosphamide, Mercaptopurine, Methotrexate, Leucovorin Calcium, Cytarabine, Etoposide, Vincristine
Study Phase: Phase 1/Phase 2
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2023
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Enrollment Status: Completed
Publish Date: June 24, 2022
Intervention Type: Drug
Study Drugs: Decitabine, Vorinostat, Filgrastim, Fludarabine, Cytarabine
Study Phase: Phase 1
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

187 Total Publications

Corrigendum to Diagnosis of post-hematopoietic stem cell transplant bronchiolitis obliterans syndrome in children: time for a rethink? Transplantation and Cellular Therapy. 2024 Aug;30(8):760-769.
Corrigendum to Diagnosis of post-hematopoietic stem cell transplant bronchiolitis obliterans syndrome in children: time for a rethink? Transplantation and Cellular Therapy. 2024 Aug;30(8):760-769.
Journal: Transplantation and cellular therapy
Published: June 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schultz's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile